The effect of landiolol on postoperative arterial fibrillation in aortic stenosis patients undergoing aortic valve replacement

The effect of landiolol on postoperative arterial fibrillation in aortic stenosis patients undergoing aortic valve replacement - The effect of landiolol on postoperative arterial fibrillation in aortic stenosis patients undergoing aortic valve replacement

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003758

Enrollment

Registered

2010-06-15

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with aortic valve stenosis undergoing isolated aortic valve replacement

Interventions

Administer a dose of 0.005mg/kg/min of landiolol for 48 hours Not administer beta-adrenergic antagonist to patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with aortic valve stenosis scheduled for isolated aortic valve replacement

Exclusion criteria

Exclusion criteria: Patients who is not candidates for beta-adrenergic antagonist therapy. 1 Preoperative LVEF<30% 2 COPD with FEV1.0<50% 3 Bronchial asthma(needs steroids or ronchodilating agents) 4 angina inversa

Design outcomes

Primary

Measure	Time frame
The incidence of arterial fibrillation on 7POD.	—

Countries

Japan

Contacts

Public ContactYoshitaka Kadoma

The Cardiovascular institute surgery

kadoma@cvi.or.jp03-3408-2151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026